(P 451) TREATMENT OUTCOMES OF GEMCITABINE AND DOCETAXEL IN PATIENTS WITH CLEAR CELL SARCOMA (CCS) OR GASTROINTESTINAL NEUROECTODERMAL TUMOR (GNET): A CASE SERIES

Author(s)

Chalothorn Wannaphut, MD

Resident
University of Hawai`i John A.Burns School of Medicine
Honolulu, Hawaii, United States

Co-Author(s)

Prapassorn Thirasastr, MD, MS

Research Scientist
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Michael S. Nakazawa, MD PhD

Assistant Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
DA

Dejka M. Araujo, MD

Professor
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Robert S. Benjamin, MD

Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Anthony P. Conley, MD

Associate Professor
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Andrew Livingston, n/a

Associate Professor
Departments of Sarcoma Medical Oncology and Paediatrics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA
Houston, Texas, United States
Joseph A. Ludwig, IV, MD

Associate Professor
MD Anderson Cancer Center
Houston, Texas, United States
Shreyaskumar Patel, MD

RR Herring Distinguished Prof and Medical Director, Sarcoma Center
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Ravin Ratan, MD, M.Ed.

Associate Professor
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Vinod Ravi, MD

Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
MZ

Maria Alejandra A. Zarzour, MD

Associate Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Elise F. Nassif Haddad, MD, PhD

Assistant Professor
MD Anderson Cancer Center
Houston, Texas, United States
Neeta Somaiah, MD (she/her/hers)

Professor and Department Chair
Department of Sarcoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
Houston, Texas, United States

Objective: CCS and GNET are rare, aggressive sarcomas characterized by EWSR1 fusions with poor response to conventional chemotherapy. However, the efficacy of gemcitabine and docetaxel (GD), a common sarcoma regimen, is not well known.

Methods: We reviewed a series of patients (pts) with CCS or GNET who received GD at MD Anderson Cancer Center. Clinical data, treatment, and outcomes were collected. Descriptive statistics was used to report BOR (best overall response), TTP (time to progression or last stable scan), and OS (time from diagnosis to death or last follow-up (f/u)).

Results: Of the 4 pts (ID 1,2,3 GNET of small bowel and ID 4 CCS of left ankle) with median age 38 yrs, 2 pts (ID 2, 3) had EWSR1-CREB while the other 2 had EWSR1-ATF fusion. All pts initially presented with localized disease and underwent curative-intent surgery before developing recurrence. Table 1 details pt characteristics, response to GD, and survival. At last f/u, all pts were alive.

Conclusion: Although CCS and GNET are generally believed to be chemo-resistant, our limited series shows efficacy with GD, suggesting that this regimen may offer clinical benefit in select pts. GD should be considered as a potential option and perhaps a comparator for newer therapies being tested in this subtype.

Table 1 Clinical Characteristics and Outcomes in Patients with CCS or GNET Treated with Gemcitabine/Docetaxel
Upload Image